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Abstract 
Elevated lipoprotein (a) (Lp[a]) is associated with cardiovascular disease (CVD) and is mainly 
genetically determined. Studies suggest a role of dietary fatty acids (FAs) in the regulation of Lp(a), 
however, no studies have investigated the association between plasma Lp(a) concentration and 
omega-6 FAs. We aimed to investigate whether plasma Lp(a) concentration was associated with 
dietary omega-6 FA intake, and plasma levels of arachidonic acid in subjects with familial 
hypercholesterolemia (FH). We included FH subjects with (n=68) and without (n=77) elevated Lp(a) 
defined as ≥75 nmol/L, and healthy subjects (n=14). Total fatty acid profile was analyzed by Gas 
Chromatography-Flame Ionization Detector analysis, and the daily intake of macronutrients 
(including the sum of omega-6 FAs: 18:2n-6, 20:2n-6, 20:3n-6 and 20:4n-6) were computed from 
completed food frequency questionnaires. FH subjects with elevated Lp(a) had higher plasma levels 
of arachidonic acid (AA) compared to FH subjects without elevated Lp(a) (P=0.03). Furthermore, 
both FH subjects with and without elevated Lp(a) had higher plasma levels of AA compared to 
controls (P<0.001). The multivariable analyses showed associations between dietary omega-6 FA 
intake and plasma levels of AA (P=0.02), and between plasma levels of Lp(a) and AA (P=0.006). 
Our data suggest a novel link between plasma Lp(a) concentration, dietary omega-6 FAs and 
plasma AA concentration, which may contribute to explain the small diet-induced increase in Lp(a) 
levels associated with lifestyle changes. Although the increase may not be clinically relevant, this 
association may be mechanistically interesting in understanding more of the role and regulation of 
Lp(a).   
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Introduction 
Lipoprotein (a) (Lp[a]) is a low density lipoprotein (LDL)-like particle bound to apolipoprotein 
(a).
(1)
 Increasing evidence supports elevated Lp(a), which may be defined as >75 nmol/L or 30 
mg/dL, for being an independent and important risk factor for cardiovascular disease (CVD).
(2)
 The 
plasma level of Lp(a) is considered to be determined mostly by the LPA gene locus,
(3)
 however, 
lifestyle-induced changes in the plasma level of Lp(a) have been reported.
(4; 5; 6; 7; 8)
 
Dietary fatty acids (FAs) differently impact CVD risk through divergent effects on the lipid 
profile.
(9)
 Despite a large body of evidence documenting the beneficial effect of replacing saturated 
FAs (SFA) with polyunsaturated FAs (PUFA) in the prevention of CVD,
(10; 11)
 recent data from 
Chowdhury et al and Ramsden et al, have reported conflicting results and concluded that there is no 
clear support of replacing SFA with PUFA. However, in 2017, the American Heart Association 
presidential advisory on dietary fats and CVD, strongly concluded that the incidence of CVD will 
be reduced when the intake of SFA is replaced with PUFA.
(12)
 Nevertheless, one of the cornerstones 
in diet recommendations when performing lifestyle changes and in the prevention of CVD, is 
replacing SFA with PUFA.
(13)
 The essential omega-6 (n-6) PUFA linoleic acid is the predominant 
dietary PUFA, and lower tissue/blood concentrations of linoleic acid have been shown to be 
inversely associated with CVD risk,
(14)
 and mortality.
(15)
 Furthermore, Marklund et al recently 
concluded that higher circulating/tissue levels of linoleic acid and possibly arachidonic acid were 
inversely associated with risk of major cardiovascular events after analyzing 30 prospective studies 
from 13 countries.
(16)
 However, some inconsistent data have also been reported. In the reanalysis of 
the Sydney Diet Heart study, it was shown that the intervention group had higher rates of death than 
controls,
(17)
 and in a Mendelian randomization study, genetically predicted linoleic acid was shown 
not to be associated with ischemic heart disease, but was associated with lower diabetes risk.
(18)
 
Recently, Berk et al found increased Lp(a) levels elicited by diet-induced weight loss after a low-fat 
diet in overweight and obese subjects.
(4)
 However, they found no change in Lp(a) levels after 
bariatric surgery
(4)
, suggesting a role of dietary FAs in the regulation of Lp(a), rather than weight 
loss per se. Indeed, randomized controlled trials (RCTs) have found Lp(a)-increasing effects of 
low-fat versus low carbohydrate diets.
(5; 6; 7; 8)
  
Subjects with familial hypercholesterolemia (FH) are characterized by increased plasma levels of 
total- and LDL-cholesterol, accelerated atherosclerosis and increased risk of premature CVD,
(19; 20)
 
and may have higher Lp(a) levels than unaffected relatives.
(21)
 Thus, FH subjects may serve as a 
suitable human model to investigate underlying mechanisms of Lp(a) modification.  
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To our knowledge, no studies have investigated whether there is an association between Lp(a) 
levels and n-6 PUFAs. Although the magnitude of the effect may not be clinically relevant, this 
association may be mechanistically interesting in understanding more of the role and the regulation 
of Lp(a). We aimed to investigate whether plasma Lp(a) concentration was associated with dietary 
omega-6 FA intake and plasma levels of arachidonic acid in subjects with FH. 
Methods 
Subjects and study design 
In this cross-sectional study, we invited FH subjects (>18 years of age) with or without elevated 
Lp(a) as defined by Lp(a) ≥ or <75 nmol/L, respectively, who were regularly followed-up at the 
outpatient Lipid Clinic, Oslo University Hospital, Norway. Other inclusion criteria were a definite 
FH diagnosis as defined by a positive DNA test (genetic FH) or a Dutch Lipid Clinic Network 
score >8
(19)
 (clinical FH) and willingness to give a blood sample. All FH subjects continued with 
their current lipid-lowering therapy during the study. Exclusion criteria were: diabetes mellitus type 
1, or pregnant or lactating women. The study visit was coordinated simultaneously with their next 
prescheduled consultation at the Lipid Clinic. Age- and sex-matched (by percentage) healthy 
controls were recruited among employees and friends of employees at the Department of Nutrition, 
University of Oslo, Norway and Oslo University Hospital, Norway. Exclusion criteria for the 
controls were: Lp(a) levels ≥75 nmol/L, cardiovascular or metabolic disease, use of lipid-lowering 
therapy, severe illness such as cancer the last 5 years, or pregnant or lactating women. All 
participants were recruited in the period September 2016-September 2017. For all participants, a 
non-fasting blood sample was obtained, and weight, height, and blood pressure were measured. 
Informed consent was obtained from all the participants. The study protocol was approved by the 
Regional Committee of Medical and Health Research Ethics, south-east region of Norway (no. 
2015/1577), and by the Privacy Ombudsman at Oslo University Hospital. The study was conducted 
in accordance with the principles of the Declaration of Helsinki.  
Total plasma fatty acid profile, FA ratios and other plasma analyses 
Plasma was obtained by EDTA tubes and kept dark, on ice until centrifugation at 4ºC for 15 
minutes, before aliquoted and stored at -80ºC until further analysis. We analysed total plasma fatty 
acid profile by Gas Chromatography-Flame Ionization Detector analysis at the commercial 
laboratory Vitas Analytical Services as previously described,
(22)
 and show the results as percentage 
of total fatty acids. We estimated certain ratios between the product and the precursor of the 
individual fatty acids in plasma (γ-linolenic acid [18:3n-6]/linoleic acid [18:2n-6]; arachidonic acid 
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[20:4n-6]/dihomo γ-linolenic acid [20:3n-6], and eicosadienoic acid [20:2n-6]/linoleic acid 18:2n-
6]), as described elsewhere.
(23)
 The plasma n-6/n-3 ratio was calculated as the total percentage of n-
6 (linoleic acid, γ-linolenic acid, eicosadienoic acid, dihomo γ-linolenic acid and arachidonic acid) 
divided by the total percentage of n-3 fatty acids (α-linolenic acid, eicosapentaenic acid, n-3 
docosapentaenic acid and docosahexaenic acid). Lp(a) was analysed by an immunoturbidimetric 
method by Roche Diagnostics at an accredited medical laboratory, Oslo University Hospital, 
Rikshospitalet, Oslo, Norway (NS-EN ISO 15189:2007). Other biochemical analyses were 
measured in plasma or serum by standard methods at the same medical laboratory. 
Dietary intake 
Nutrient intake was recorded by a self-administered 256-item food frequency questionnaire (FFQ) 
completed according to a description, both received by mail. In case of incorrect completion, the 
participants were interviewed at the study visit or by phone. The FFQ is developed at the 
Department of Nutrition, University of Oslo, Norway and has been validated and described in detail 
elsewhere.
(24)
 Briefly, intake frequencies (monthly, weekly or daily) and portion sizes in predefined 
household units were registered. Open spaces were available for description of unlisted food items, 
which were included in the nutrient calculations. The food database AE-14 and the software 
“Kostberegningssystem” (version 7.3, 2017) were used to compute the daily intake of energy and 
nutrients. The food database used (AE-14) is based on the official Norwegian Food Composition 
Table (http://www.norwegianfoodcomp.no/), supplemented with data from calculated recipes and 
other databases, and has a large number of fatty acids including n-6 PUFAs. Total dietary n-6 
PUFA is the sum of 18:2n-6, 20:2n-6, 20:3n-6 and 20:4n-6. 
Statistics 
Kruskal-Wallis test was used for all comparisons between the three groups as regards continuous 
variables. Pair-wise comparisons (posthoc tests) were performed with Mann-Whitney test, and 
presented both unadjusted and Bonferroni-adjusted. The results are presented as medians (25th -
75th percentile) in the tables and the text, and median (min-max) in figures. Chi-square test or 
Fisher’s exact test were used for categorical data and presented as frequency (percentage) in tables. 
Linear regression analysis was performed to study the association between the dietary intake of total 
n-6 PUFA, linoleic acid and arachidonic acid (all in energy percentage [E%]), and plasma 
arachidonic acid after adjustment for potential confounding variables among FH patients that 
completed FFQ. Furthermore, logistic regression analysis was used to adjust for potential 
confounding variables when studying the association between plasma arachidonic acid and plasma 
Lp(a) concentration. Results are presented as regression coefficients and odds ratios (ORs), 
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respectively, with 95% confidence intervals (CIs). The regression analyses were guided by directed 
acyclic graphs. Statistical analyses were performed by IBM SPSS Statistics 24.ink. P-values (two-
tailed) <0.05 were considered significant.  
 
Results 
Characteristics 
In total, FH subjects with (n=68) and without (n=77) elevated Lp(a) levels defined as ≥ and < 75 
nmol/L plasma Lp(a), and 14 healthy controls were included in the study (Supplementary Figure 1). 
All the FH subjects had a genetically verified diagnosis except for four who had clinical FH
(19)
 
(Table 1). All FH patients used lipid-lowering therapy, and had generally received dietary 
counselling as part of their standard follow-up at the Lipid Clinic. Both groups of FH subjects had 
significantly higher body mass index (BMI) (P>0.001) and systolic blood pressure (P=0.003) than 
the healthy controls. More FH subjects with elevated Lp(a) levels had experienced CVD (P=0.02) 
and were more often treated with PCSK9-inhibitors (P=0.01) than the FH subjects without elevated 
Lp(a). Although blood samples were taken non-fasting, median triglyceride levels were not elevated 
according to European guidelines, where triglyceride levels ≥1.7 mmol/L is considered elevated.(25) 
However, 19.1%, 19.5% and 14.3% of the FH subjects with elevated Lp(a), FH subjects without 
elevated Lp(a) and controls had levels ≥1.7 mmol/L, respectively. 
Plasma FA profile and ratios of FAs 
For plasma levels of n-6 PUFAs, we found several significant differences between the groups 
(Figure 1). First, we observed higher level of arachidonic acid (20:4n-6) in FH subjects with 
elevated Lp(a) compared to FH subjects without elevated Lp(a) (P=0.03, Figure 1a). Furthermore, 
the levels of arachidonic acid (20:4n-6), dihomo-γ-linolenic acid (20:3n-6) and γ-linolenic acid 
(18:3n-6) were all higher in both FH groups compared to the healthy controls (P<0.001 for all, 
Figure 1a, b, c, respectively). Contrary, the level of linoleic acid (18:2n-6) was lower in both FH 
groups compared to healthy subjects (P<0.001 for both, Figure 1d), and the level of eicosadienoic 
acid (20:2n-6) was lower in FH with elevated Lp(a) compared to healthy subjects (P<0.01, Figure 
1e). For the plasma levels of n-3 PUFA (Table 2), we found lower levels of α-linolenic acid (18:3n-
3) in both FH groups compared to the healthy controls (P<0.005 for both). The level of 
docosahexaenoic acid (22:6n-3) was lower in the FH subjects without elevated Lp(a) than in the 
healthy controls (P=0.02). A few significant differences between the groups were also observed 
among the plasma levels of monounsaturated fatty acids (MUFA) and SFA (Table 2).  
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In order to investigate the n-6 PUFA pathway more in detail, we estimated the ratios of certain n-6 
PUFAs (as described in methods). The ratios 18:3n-6/18:2n-6 and 20:4n-6/20:3n-6 were higher in 
both FH groups than in the healthy controls (P<0.05 for all, Figure 2a).  
Dietary intake and dietary pattern 
FH subjects with elevated Lp(a) had higher intake of dietary fibre (E %) and lower intake of 
cholesterol (mg) compared to FH subjects without elevated Lp(a), and lower intake of trans-fatty 
acids (E %) than healthy controls (P=0.03 for all, Table 3). There was an overall significant 
difference in SFA intake between the three groups (P=0.03), however, no significant differences 
were observed in the pair-wise comparisons with Bonferroni-adjustment. We found no significant 
differences between the three groups regarding MUFA, total PUFA, n-3 or n-6 intake (E % for all, 
Table 3). In order to explain the differences in dietary intake between the FH groups, we explored 
dietary pattern between FH subjects with and without elevated Lp(a). Compared to FH subjects 
without elevated Lp(a), FH subjects with elevated Lp(a) had lower intake of cakes 7.9 (2.1-18.8) vs. 
13.6 (7.5-21.4) g/day P=0.006; sweets 12.0 (4.6-29.1) vs 18.8 (12.0-38.2) g/day P=0.02, and non-
significantly lower intake of cheese 22.2 (12.7-35.1) vs 28.2 (16.0-49.2) g/day P=0.08. There was 
no difference in total intake of food (g/day) between the FH groups (data not shown). 
Multivariable analyses 
The results of multiple linear regression analyses of intake of n-6 PUFA in relation to plasma 
arachidonic acid among FH subjects (n=139) were unchanged after adjustment for age, sex and 
BMI (crude regression coefficients: 0.32 [95% CI 0.05, 0.60], P=0.02 and adjusted regression 
coefficients: 0.32 [95% CI 0.05, 0.59], P=0.02, for every E % change in n-6 PUFA). Furthermore, 
the results of multiple linear regression analyses of intake of linoleic acid in relation to plasma 
arachidonic acid among FH subjects (n=139) were unchanged after adjustment for age, sex and 
BMI (crude regression coefficients: 0.32 [95% CI 0.05, 0.59], P=0.02 and adjusted regression 
coefficients: 0.32 [95% CI 0.05, 0.60], P=0.02, for every E % change in linoleic acid). The results 
of multiple linear regression analyses of intake of arachidonic acid in relation to plasma arachidonic 
acid among FH subjects (n=139) were unchanged after adjustment for age, sex and BMI (crude 
regression coefficients: 4.9 [95% CI -11.3, 21.1], P=0.55 and adjusted regression coefficients: 0.79 
[95% CI -15.8, 17.3], P=0.93, for every E % change in arachidonic acid).  
The results of the logistic regression analyses comparing plasma arachidonic acid levels between 
the two FH groups were unchanged after adjustment for age, sex, BMI, use of PCSK9-inhibitors 
and cholesterol intake (crude and adjusted ORs were 1.29 [95 % CI 1.08, 1.54], P=0.005 and 1.31 
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[95 % CI 1.08, 1.58], P=0.006 for every unit change in plasma arachidonic acid for FH subjects 
with elevated Lp[a] versus FH subjects without elevated Lp[a]). 
Discussion 
In the present study, we found that FH subjects with elevated Lp(a) levels had higher plasma levels 
of arachidonic acid compared to FH subjects without elevated Lp(a). Furthermore, both FH subjects 
with and without elevated Lp(a) had higher plasma levels of arachidonic acid compared to controls. 
Additionally, the associations between n-6 PUFA intake and plasma arachidonic acid, and between 
plasma arachidonic acid and Lp(a) in FH subjects, further support our hypothesis of a relationship 
between n-6 PUFA and Lp(a). We propose a novel link between n-6 PUFA intake, plasma 
arachidonic acid and elevated Lp(a) levels.  
Arachidonic acid and other higher n-6 PUFA derivatives are derived during desaturation and 
elongation processes from the precursor and essential FA linoleic acid,
(26)
 however, the plasma 
levels of arachidonic acid may also depend on other processes such as turnover, oxidation etc.
(27)
 
Our results from both univariable and multivariable analyses suggest an association between plasma 
arachidonic acid level and plasma Lp(a) level in FH subjects. Furthermore, the multivariable 
analyses show associations between plasma arachidonic acid and n-6 PUFA intake in FH subjects, 
whereof dietary linoleic acid, but not arachidonic acid, as expected, is the n-6 PUFA associated with 
plasma arachidonic acid level. These results support that linoleic acid, which is the most abundant 
n-6 PUFA in the diet, is the driver of the association between dietary n-6 PUFA and plasma level of 
arachidonic acid. Collectively, this may support an association between plasma Lp(a) concentration, 
dietary n-6 PUFAs and plasma arachidonic acid level. Consistent with our results, Hikita et al have 
shown higher plasma Lp(a) concentration and lower ratio of eicosapentaenoic acid/arachidonic acid 
in patients with compared to without increased risk of CVD.
(28)
 Recently, lipid apheresis was found 
to reduce linoleic acid and arachidonic acid in plasma of hyperlipidemic patients, concomitant  with 
a reduction in Lp(a) levels, further indicating an indirect link between n-6 PUFAs and lipoproteins 
such as LDL and Lp(a).
(29; 30)
 Previously, Li et al showed that omnivores had both higher Lp(a) 
levels and higher concentration of arachidonic acid in serum phospholipids,
(31)
 possibly due to 
increased direct availability of arachidonic acid from their meat intake. However, the present study 
is, to our knowledge, the first to show a link between n-6 PUFA intake, plasma arachidonic acid and 
plasma Lp(a) concentration in FH subjects.  
The enzymes Δ-6 desaturase (D6D, rate-limiting) and D5D convert linoleic acid to γ-linolenic acid, 
and dihomo-γ-linolenic acid to arachidonic acid, respectively, and the ratios 18:3n-6/18:2n-6 and 
20:4n-6/20:3n-6 may be used as surrogate markers of D6D and D5D activities, respectively.
(23)
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Thus, our results may suggest higher D6D and D5D activity leading to lower plasma levels of 
linoleic acid and higher levels of downstream n-6 PUFAs such as γ-linolenic acid, dihomo- γ-
linolenic acid and arachidonic acid in FH subjects compared to control subjects. Contrary, plasma 
levels of eicosadienoic acid were lower in FH subjects compared with controls. The conversion of 
linoleic acid to eicosadienoic acid is a “side track” from the direct conversion towards arachidonic 
acid
(32)
, possibly indicating a preferred metabolism towards arachidonic acid in FH subjects. 
Desaturases are regulated through the transcription factor, sterol regulatory element binding protein-
1c, by dietary fat and cholesterol.
(33)
 Lower dietary intake of SFA and cholesterol may potentially 
be surrogate markers of higher PUFA intake, and may thus differentially impact the regulation of 
D6D in FH subjects with elevated Lp(a). Thus, FA regulation of D6D may also partially explain the 
previously observed increased plasma levels of Lp(a) after lifestyle-induced, but not bariatric, 
weight reduction in the study by Berk et al,
(4)
 further supporting the possible biological link 
between Lp(a) and arachidonic acid. However, the link between n-6 PUFA and Lp(a) needs further 
investigation. 
Common for the previously mentioned dietary RCTs, the intervention groups lowered the intake of 
SFA, but also increased the intake of carbohydrates 
(5; 6; 7; 8)
, in particular dietary fibre intake
(6; 8)
. In 
line with this, we also find a higher intake of dietary fibre between the FH subjects with versus 
without elevated Lp(a). Hence, it cannot be ruled out that the diet-induced Lp(a) response may be a 
synergy effect of lowering SFA/increasing PUFA and increasing dietary fibre. In the present study 
it is likely that all FH individuals received the same dietary advices regarding their diagnosis. 
However, the adherence to a beneficial diet is potentially better in the FH subjects with elevated 
Lp(a) concentration since they had experienced more events of CVD and were more often treated 
with PCSK9-inhibitors, potentially increasing the awareness of their increased CVD risk. Data on 
dietary pattern showed a lower intake of cakes, sweets and cheese in FH subjects with elevated Lp(a) 
compared to FH subjects without elevated Lp(a), indicating healthier food choices among FH 
subjects with elevated Lp(a). Although being mechanistically interesting, the diet-induced increase 
in plasma Lp(a) concentration is, however, probably less clinically significant since a reduction of 
approximately 100 mg/dL (~240 nmol/L when converted according to Gencer et al
(34)
) in Lp(a) in a 
short-time perspective may be required to reduce CVD risk with the same magnitude achieved by 
lowering LDL-cholesterol by 1 mmol/L.
(35)
 
The FA content in phospholipids is dominated by n-6 PUFAs, in particular linoleic acid and 
arachidonic acid, rather than n-3 PUFAs.
(36)
 Since, Lp(a) transport more than 90% of oxidized 
phospholipids (OXPL) in plasma, representing an atherogenic feature,
(37)
 and there is an association 
between a dietary marker of increased PUFA intake and the proportion of different phospholipids, 
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(38)
 it is tempting to speculate that increased levels of arachidonic acid change the proportion of 
phospholipids, possibly increasing OXPL. Furthermore, linoleic and arachidonic acid have been 
shown to be antagonists of farnesoid X receptor (FXR),
(39)
 and FXR activation has been shown to 
decrease Lp(a).
(40)
 Thus, n-6 PUFA may inhibit FXR, mediating an increase in Lp(a) required for 
transporting increased OXPL, and this small increase in Lp(a) could therefore represent a 
counteracting and even atheroprotective mechanism mediated by n-6 PUFA. 
Major strengths of the study are that we show associations between plasma arachidonic acid and 
Lp(a) concentrations in both univariable and multivariable analyses. Further, we included mainly 
genetically verified FH subjects with and without elevated Lp(a) with dietary data. A major 
limitation is the low number of control subjects. The main aim of the study was to compare FH 
subjects with and without elevated Lp(a) levels, however, we chose to include a small number of 
healthy controls to have a reference “point” since a number of the analyses we measured (including 
the plasma fatty acid profile) does not have established prespecified cut-off points. Other limitations 
are that the study is explorative and hypothesis generating; the use of FA ratios as markers of 
enzyme activities since the plasma level of the product and the precursor FAs may be biased by 
synthesis, turnover, oxidation, medication etc; and measuring plasma FAs as relative rather than 
absolute concentrations. However, a major scope of the study was to explore the relation between 
Lp(a) concentration and plasma levels of specific FAs. Thus, we believe that relative values of FA 
are more meaningful in the present manuscript. Furthermore, FAs in red blood cells would have 
been a better marker for long-term diet intake reflecting FFQ data, compared to plasma FAs from 
non-fasting blood samples that mainly reflect short-term dietary intake.
(41)
 Nevertheless, the FH 
patients had generally been followed-up at the Lipid Clinic for years and received dietary 
counselling as part of their treatment. Furthermore, we have previously shown a more beneficial 
diet in children and young adults with FH compared to the general population.
(42)
 Also, we recently 
showed that 87% of all FH adults, that had been treated at 3 Norwegian lipid clinics, received 
dietary counselling.
(43)
 Dietary pattern was measured using a score divided into three categories. 
LDL-C levels were lower among those with a diet score in the healthiest category at last visit,  than 
in subjects with a score in the most unhealthy category (3.2 [1.2] vs. 4.4 [2.1] mmol/L, P<0.001). 
After follow-up at the lipid clinics, the number of subjects with a diet score in the healthiest diet 
category doubled. These data are also supported by data from the SAFEHEART-study which 
showed that adults with FH have healthier dietary habits with lower consumption of SFA compared 
to non-FH.
(44)
 Taken together, this may support the notion that FH subjects have long-lasting 
improved dietary habits, which may be reflected in plasma FAs even if plasma FAs mainly reflect 
short-term dietary intake.  
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core . Erasm
us M
C
 Rotterdam
, on 18 Jul 2019 at 12:38:12 , subject to the C
am
bridge C
ore term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114519001600
 Accepted manuscript 
11 
 
In conclusion, FH subjects with elevated plasma Lp(a) levels had higher plasma levels of the n-6 
PUFA arachidonic acid. Furthermore, dietary n-6 PUFA intake was associated with plasma 
arachidonic acid, where dietary linoleic acid seemed to be the main driver of the dietary n-6 PUFAs 
in this association. Our data suggest a novel link between plasma Lp(a) concentration, dietary 
omega-6 FAs and plasma arachidonic acid concentration, which may contribute to explain the small 
diet-induced increase in Lp(a) levels associated with lifestyle changes. Although the increase may 
not be clinically relevant, this association may be mechanistically interesting in understanding more 
of the role and the regulation of Lp(a). 
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Legends 
 
Figure 1. Plasma levels of arachidonic acid (a),  dihomo-γ-linolenic acid (b), γ-linolenic acid (c), 
linoleic acid (d) and eicosadienoic acid (e) in FH subjects with (n=68) or without (n=77) elevated 
Lp(a) and healthy controls (n=14). Data are analysed by Kruskal-Wallis test with Bonferroni 
corrected posthoc comparisons between the groups when significant and given as median (min-max) 
percent of total fatty acids. FAs, fatty acids; FH familial hypercholesterolemia; Lp(a), lipoprotein (a) 
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core . Erasm
us M
C
 Rotterdam
, on 18 Jul 2019 at 12:38:12 , subject to the C
am
bridge C
ore term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114519001600
 Accepted manuscript 
18 
 
 
Figure 2. Estimated ratios as surrogate markers of delta 6 desaturase (a), delta 5 desaturase and 
elongase 5 in FH subjects with (n=68) or without (n=77) elevated Lp(a) and healthy controls (n=14). 
The ratios as calculated as product divided by precursor as indicated on the y-axes. Data are 
analysed by Kruskal-Wallis test with Bonferroni corrected posthoc comparisons between the groups 
when significant and given as median (min-max). FH familial hypercholesterolemia; Lp(a), 
lipoprotein (a). 
Supplementary Figure 1. Flow chart showing the recruitment process of the cross-sectional study. 
FH familial hypercholesterolemia; Lp(a), lipoprotein (a).
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Table 1. Characteristics of the participants                     
   
 
FH subjects 
 
Healthy subjects 
 
Unadjusted 
 
Adjusted 
 
Lp(a) ≥ 75 nmol/L Lp(a) < 75nmol/L  
 
  
 
P
*
 P
†
 P
‡
 P
§
 
 
P
†
 P
‡
 P
§
 
 
 n=68 n=77 
 
n=14 
     
      
Descriptives                         
   Age, years 48  (32-61) 44  (31-59) 
 
44  (34-50) 0.74 
       Sex, female 35  (51.5) 41  (53.2) 
 
8  (57.1) 0.92 
       BMI, kg/m
2
 25.9  (22.2-28.6) 25.7  (22.5-29.2) 
 
21.5  (19.1-22.4) <0.001 0.81 <0.001 <0.001 
 
1.00 <0.001 <0.001 
SBP, mmHg 126  (120-136)|| 128  (115-137) 
 
114  (107-121) 0.002 0.94 0.001 0.001 
 
1.00 0.003 0.003 
DBP, mmHg 74  (71-82)¶ 77  (69-82) 
 
72  (66-74) 0.06 
       Current smoking 7  (10.3) 11  (14.3) 
 
0 
 
0.04 
       Genetic diagnosis 66  (97.1) 75  (97.4) 
    
1.00 
   
1.00 
  CVD 15  (22.1) 6  (7.8) 
    
0.02 
   
0.02 
  Blood biochemistry 
               Tchol, mmol/L 4.5  (3.9-5.3) 4.7  (4.0-5.6) 
 
5.0  (4.5-5.3) 0.36 
       HDL-C, mmol/L 1.3  (1.1-1.6) 1.5  (1.2-1.7) 
 
1.6  (1.3-2.1) 0.08 
       LDL-C, mmol/L 2.7  (2.1-3.3) 2.8  (2.3-3.6) 
 
3.0  (2.4-3.4) 0.6 
       Triglycerides, mmol/L 1.0  (0.7-1.4) 1.0  (0.7-1.6) 
 
1.0  (0.8-1.5) 0.9 
       ApoA1, g/L  1.4  (1.3-1.6) 1.4  (1.2-1.6) 
 
1.5  (1.4-1.7) 0.39 
       ApoB, g/L  1.0  (0.8-1.1) 0.9  (0.8-1.1) 
 
0.8  (0.7-1.0) 0.15 
       Lp(a), nmol/L  224  (170-326) 7  (7-20) 
 
10  (7-28) 
        Glucose, mmol/L 5.3  (5.0-5.8) 5.2  (4.9-5.6) 
 
5.1  (4.6-5.5) 0.1 
       
https://doi.org/10.1017/S0007114519001600
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Medical treatment 
               Statins 63  (92.6) 70  (90.9) 
    
0.94 
   
0.94 
  PCSK9-inhibitor 18  (26.5) 8  (10.4) 
    
0.01 
   
0.01 
  Colesevelam 10  (14.7) 13  (16.9) 
    
0.90 
   
0.90 
  Ezetimibe 49  (72.1) 47  (61) 
    
0.22 
   
0.22 
  Acetylsalicylic acid 25  (36.8) 19  (24.7)         0.16       0.16     
Data are presented as median (25th-75th percentile) for continuous variables, and frequency (%) for categorical variables. 
    Apo, apolipoprotein; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; FH, familial hypercholesterolemia;  
 g/L, grams per Litre; HDL-C, high density lipoprotein cholesterol; kg, kilograms; LDL-C, low density lipoprotein cholesterol; Lp(a), lipoprotein (a);  
m, meters; mmHg, millimeter mercury; mmol/L, millimoles per Litre; nmol/L, nanomoles per Litre; PCSK9, proprotein convertase subtilisin/kexin type 
9; SBP, systolic blood pressure; Tchol, total cholesterol. 
*
Kruskal-Wallis test or chi-square test between the three groups 
           
†
Mann Whitney test or chi-square test between FH subjects  Lp(a) ≥ 75 nmol/L and FH subjects Lp(a) < 75 nmol/L,  
     Mann Whitney test between:
 ‡FH subjects  Lp(a) ≥ 75 nmol/L and controls, §FH subjects  Lp(a) < 75 nmol/L and controls 
    P-values from the Mann Whitney U test are shown as unadjusted and Bonferroni-adjusted. 
        ||n=62, ¶n=61 
                 
https://doi.org/10.1017/S0007114519001600
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Table 2. Fatty acids in plasma  
                 FH subjects   Healthy subjects   Unadjusted   Adjusted 
 
Lp(a) ≥ 75 nmol/L  
Lp(a) < 
75nmol/L  
   
P
*
 P
†
 P
‡
 P
§
 
 
P
†
 P
‡
 P
§
 
  n=68 n=77   n=14                 
n-3 PUFA, % of total FAs 
               
ALA, 18:3n-3 0.62  (0.46-0.77) 0.62  (0.49-0.83) 
 
0.94  (0.73-1.12) <0.001 0.66 
<0.00
1 0.001 
 
1.00 <0.001 0.003 
EPA, 20:5n-3 1.72  (1.04-2.59) 1.42  (1.07-2.08) 
 
1.66  (1.03-2.04) 0.60 
       DPA, 22:5n-3 0.60  (0.50-0.67) 0.54  (0.49-0.61) 
 
0.59  (0.55-0.61) 0.10 
       DHA, 22:6n-3 2.48  (1.97-3.19) 2.38  (2.01-2.99) 
 
3.03  (2.76-3.43) 0.02 0.59 0.02 0.006 
 
1.00 0.06 0.02 
MUFA, % of total FAs 
               Palmitoleic acid, 16:1n-7 1.65  (1.34-2.02) 1.55 (1.26-1.90) 
 
1.33  (1.17-1.81) 0.27 
       Oleic acid, 18:1n-9 22.1  (19.4-24.5) 21.3  (19.5-24.3) 
 
19.6  (18.7-20.3) 0.02 0.69 0.01 0.04 
 
1.00 0.03 0.12 
cis-Vaccenic acid, 18:1n-7 1.69  (1.53-1.88) 1.60  (1.46-1.77) 
 
1.40  (1.35-1.53) 0.001 0.07 
<0.00
1 0.005 
 
0.21 <0.001 0.02 
https://doi.org/10.1017/S0007114519001600
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11-Eicosenoic acid, 20:1n-9 0.17  (0.14-0.21) 0.17  (0.11-0.22) 
 
0.11  (0.11-0.14) 0.06 
       SFA, % of total FAs 
               Lauric acid, 12:0 0.08  (0.05-0.12) 0.08  (0.06-0.12) 
 
0.12  (0.08-0.15) 0.29 
       Myristic acid, 14:0 0.78  (0.64-0.94) 0.80  (0.64-1.02) 
 
0.88  (0.80-0.97) 0.26 
       
Pentadecylic acid, 15:0 0.17  (0.14-0.19) 0.16  (0.14-0.20) 
 
0.21  (0.19-0.22) 0.001 0.43 
<0.00
1 0.001 
 
1.00 <0.001 0.003 
Palmitic acid, 16:0 19.3  (18.4-20.5) 19.6  (18.9-20.8) 
 
19.7  (19.2-20.3) 0.40 
       Stearic acid, 18:0 7.06  (6.73-7.56) 7.00  (6.51-7.52) 
 
6.79  (6.47-7.04) 0.20 
       
Arachidic acid, 20:0 0.33  (0.29-0.38) 0.32  (0.28-0.36) 
 
0.25  (0.22-0.26) <0.001 0.4 
<0.00
1 <0.001 
 
1.00 <0.001 
<0.00
1 
Behenic acid, 22:0 0.77  (0.68-0.89) 0.76  (0.66-0.83) 
 
0.62  (0.60-0.70) 0.02 0.61 0.02 0.06 
 
1.00 0.06 0.18 
Lignoceric acid, 24:0 0.55  (0.46-0.69) 0.56  (0.47-0.67)   0.39  (0.36-0.62) 0.07               
Data are presented as median (25 th-75th percentile). 
             ALA, alpha-linolenic acid; C, carbon; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; FAs, fatty acids;  
FH, familial hypercholesterolemia; Lp(a), lipoprotein (a); MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, 
saturated fatty acids 
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*
Kruskal-Wallis test between the three groups 
             Mann Whitney test between: 
†FH subjects  Lp(a) ≥ 75 nmol/L and FH subjects Lp(a) < 75 nmol/L, ‡FH subjects  Lp(a) ≥ 75 nmol/L and 
controls,  §FH subjects  Lp(a) < 75 nmol/L and controls P-values from the Mann Whitney U test are shown as unadjusted and 
Bonferroni-adjusted. 
   
Table 3. Intake of energy and macronutrients  
             FH subjects   Healthy controls   Unadjusted   Adjusted 
 
Lp(a) ≥ 75 nmol/L  Lp(a) < 75nmol/L  
 
n=14 P* P
†
 P
‡
 P
§
 
 
P
†
 P
‡
 P
§
 
  n=66 n=73                     
Energy, kJ 9187 (7588-10796) 9752 (8466-11468) 
 
10400 (9334-12710) 0.08 
       Protein, E% 17.9 (16.5-19.5) 17.8 (16.2-19.3) 
 
18.7 (15.3-19.7) 0.91 
       Fat, E% 31.2 (28.1-35.2) 33.2 (30.0-35.8) 
 
33.3 (31.5-35.4) 0.21 
       SFA, E% 9.1 (7.6-10.3) 9.5 (8.3-11.6) 
 
10.0 (9.1-11.8) 0.03 0.03 0.03 0.41 
 
0.09 0.09 1.00 
TFA, E% 0.2 (0.1-0.2) 0.2 (0.1-0.3) 
 
0.3 (0.2-0.3) 0.03 0.28 0.01 0.06 
 
0.84 0.03 0.18 
Cis-MUFA, E% 12.1 (10.6-14.1) 12.9 (11.6-14.0) 
 
12.8 (11.5-13.6) 0.43 
       Cis-PUFA, E% 6.9 (6.0-8.0) 6.8 (5.8-7.8) 
 
6.7 (5.6-7.6) 0.64 
       n-3 PUFA, E% 1.8 (1.4-2.4) 1.9 (1.2-2.4) 
 
1.8 (1.2-2.2) 0.72 
       n-6 PUFA E% 4.8 (4.1-5.6) 4.8 (4.1-5.4) 
 
4.7 (4.1-6.0) 0.95 
       Linoleic acid, E% 4.7 (3.9-5.5) 4.7 (4.0-5.3) 
 
4.6 (4.0-5.9) 0.93 
       Arachidonic acid, E% 0.05 (0.04-0.07) 0.06 (0.05-0.07) 
 
0.06 (0.04-0.07) 0.16 
       Carbohydrates, E% 44.0 (39.5-49.3) 43.4 (39.4-46.8) 
 
43.3 (41.5-46.8) 0.64 
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Starch, E% 21.8 (18.5-26.4) 21.6 (17.9-24.6) 
 
23.8 (20.3-30.7) 0.19 
       Dietary fibre, E% 2.9 (2.5-3.5) 2.6 (2.2-3.0) 
 
2.7 (2.5-2.8) 0.03 0.01 0.19 0.6 
 
0.03 0.57 1.00 
Monodisaccharides, E% 18.0 (14.7-22.0) 18.1 (15.3-22.5) 
 
16.7 (15.0-19.7) 0.52 
       Sugar, E% 3.8 (2.4-6.4) 4.7 (3.3-6.8) 
 
4.5 (2.3-5.5) 0.08 
       Alcohol, E% 2.6 (1.1-4.1) 2.4 (1.0-4.6) 
 
1.3 (0.9-5.1) 0.82 
       Cholesterol, mg  232 (180-321) 289 (230-370)   268 (194-331) 0.03 0.01 0.4 0.37   0.03 1.00 1.00 
Data are presented as median (25 th-75th percentile). 
          E%, energy percent; FH, familial hypercholesterolemia; kJ, kilo Joule; Lp(a), lipoprotein (a); mg, milligram; nmol/L; MUFA, monounsaturated fatty 
acids; 
  n-3/6, omega-3/6; nanomoles per litre; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; TFA, trans-unsaturated fatty acids. 
  
*
Kruskal-Wallis test between the three groups 
           Mann Whitney U test between: 
†FH subjects  Lp(a) ≥ 75 nmol/L and FH subjects Lp(a) < 75 nmol/L, 
        
‡FH subjects  Lp(a) ≥ 75 nmol/L and controls, §FH subjects  Lp(a) < 75 nmol/L and controls 
        P-values from the Mann Whitney U test are shown as unadjusted and Bonferroni-adjusted. 
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